2023-505023-31-00招募中3 期
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 549
- 试验地点
- 100
- 主要终点
- Disease-Free Survival (DFS)
研究概览
简要总结
To compare disease-free survival (DFS) as assessed by investigator for participants treated with belzutifan plus pembrolizumab versus those receiving placebo plus pembrolizumab
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Has histologically or cytologically confirmed diagnosis of renal cell carcinoma (RCC) with clear cell component per American Joint Committee on Cancer (AJCC) (8th Edition), with or without sarcomatoid features
- •Has intermediate-high risk, high risk, or M1 no evidence of disease (NED) RCC as defined by the following pathological tumor-node metastasis and tumor grading: (1) Intermediate-high risk RCC: pT2, Grade 4 or sarcomatoid, N0, M0; pT3, any grade, N0, M0 (2) High risk RCC: pT4, any grade N0, M0; pT any stage, any Grade N+, M0 (3) M1 NED RCC participants who present not only with the primary kidney tumor but also solid, isolated, soft tissue metastases that can be completely resected at one of the following: the time of nephrectomy (synchronous) or, ≤2 years from nephrectomy (metachronous)
- •Has undergone complete resection of the primary tumor (partial or radical nephrectomy) and complete resection of solid, isolated, soft tissue metastatic lesion(s) in M1 NED participants
- •Must have undergone a nephrectomy and/or metastasectomy ≤12 weeks prior to randomization
- •Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 10 days before randomization
- •Male participants must agree to continue contraception at least 7 days after the last dose of belzutifan/placebo
- •Female participants of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of pembrolizumab or at least 30 days after last dose of belzutifan/placebo, whichever occur last
- •Has adequate organ function
排除标准
- •Has had a major surgery, other than nephrectomy plus resection of preexisting metastases for M1 NED participants, within 4 weeks prior to randomization
- •Has a known additional malignancy (other than RCC treated with nephrectomy and/or metastasectomy) that is progressing or has required active treatment within the past 3 years
- •Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs); replacement therapy is allowed
- •Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- •Has an active infection, requiring systemic therapy
- •Has a known history of human immunodeficiency virus (HIV) infection, a known history of hepatitis B or known active Hepatitis C virus infection
- •Has had an allogenic tissue/solid organ transplant
- •Has a pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
- •Has clinically significant cardiovascular disease within 6 months from first dose of study intervention
- •Has other clinically significant disorders such as: serious active nonhealing wound/ulcer/bone fracture; requirement for hemodialysis or peritoneal dialysis
- •Has preexisting brain or bone metastatic lesions
- •Has received prior systemic therapy for RCC
- •Has received prior radiotherapy for RCC
- •Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention; administration of killed vaccines are allowed
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
结局指标
主要结局
Disease-Free Survival (DFS)
Disease-Free Survival (DFS)
次要结局
- Number of Participants Who Experience At Least One Adverse event (AE)
- Overall Survival (OS)
- Number of Participants Who Discontinue Study Treatment Due to an AE
- Disease Recurrence-Specific Survival 1 (DRSS1)
- Disease Recurrence-Specific Survival 2 (DRSS2)
- Change From Baseline in Health-Related Quality-of-Life (HRQoL) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 29 and 30 Score
- Change From Baseline in Physical Functioning Using the EORTC QLQ-C30 Items 1- 5 Score
- Change From Baseline in Role Functioning Using the EORTC QLQ-C30 Items 6 and 7 Score
- Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) Items 1-9 Score
研究者
Manish Sharma, MD
Scientific
Merck Sharp & Dohme LLC
研究点 (100)
Loading locations...
相似试验
进行中（未招募）
3 期
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)NCT06211764Janssen Research & Development, LLC272
招募中
3 期
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerNCT06919965Janssen Research & Development, LLC220
已完成
3 期
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C MutationColorectal Cancer (CRC)NCT05198934Amgen160
终止
3 期
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)Ovarian CancerNCT01170650Endocyte441
招募中
3 期
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in HER2 Positive Advanced Gastric or GEJ Adenocarcinoma2023-508253-98-00Merck Sharp & Dohme LLC167